Last reviewed · How we verify
Schistosomiasis due to S. Mansoni — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cysticide | Cysticide | Merck KGaA, Darmstadt, Germany | Bile salt export pump, Glutathione S-transferase class-mu 26 kDa isozyme, High voltage-activated calcium channel beta subunit CavB1 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Merck KGaA, Darmstadt, Germany · 1 drug in Schistosomiasis due to S. Mansoni
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Schistosomiasis due to S. Mansoni:
- Schistosomiasis due to S. Mansoni treatment updates — RSS
- Schistosomiasis due to S. Mansoni treatment updates — Atom
- Schistosomiasis due to S. Mansoni treatment updates — JSON
Cite this brief
Drug Landscape (2026). Schistosomiasis due to S. Mansoni — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/schistosomiasis-due-to-s-mansoni. Accessed 2026-06-10.
Related
- Schistosomiasis due to S. Mansoni full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing